Essentia Omega

Essentia (formerly Essentia Metabolic) was a clinical-stage biotechnology company focused on developing novel omega-3 fatty acid-based therapeutics for metabolic and cardiovascular diseases. The company's lead research centered on highly purified omega-3 compositions designed to target specific G protein-coupled receptors involved in lipid metabolism and inflammation. Essentia's approach aimed to provide more potent and targeted alternatives to existing fish oil-derived treatments. The company was eventually acquired by KD Pharma Group, a leading global manufacturer of highly purified omega-3 fatty acids, to integrate its intellectual property and clinical development expertise into KD Pharma's pharmaceutical division.